ArticlePLOS global public health2025
Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unraveling PrEP persistence: mental health and substance use among adolescent girls and young women in an implementation program.AIDS (London, England) · 2026Article
- Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Adolescent girls and young women (AGYW) in sub-Saharan Africa are at substantial risk of HIV acquisition and could benefit from oral pre-exposure prophylaxis (PrEP) for HIV prevention. Substance use may result in poor adherence, diminishing PrEP effectiveness. The effects of substance use on PrEP adherence in AGYW within the African context have not been extensively studied. We sought to determine the prevalence of substance use and its association with PrEP adherence in AGYW enrolled in an HIV prevention trial. The HIV Prevention Trials Network (HPTN) 082 study enrolled healthy, HIV-negative, sexually active young women (16-25 years) from Cape Town, Johannesburg, South Africa, and Harare, Zimbabwe, between October 2016-2018. Participants were offered oral PrEP. Data on hazardous drinking was collected using the AUDIT-C questionnaire and defined as having an AUDIT-C score ≥3. Data on substance use was collected using the abridged ASSIST questionnaire, with responses categorized as 0 (never used a substance) and 1 (ever substance use). Tenofovir-diphosphate (TFV-DP) levels in dried blood spots at weeks 13, 26, and 52 were used to measure PrEP adherence. Low adherence was defined as TFV-DP concentration <700 fmol/punch. Repeated measure multinomial regression modeling was used to determine associations between substance use and hazardous drinking vs PrEP adherence. Of the 451 participants enrolled, 427 (95%) initiated PrEP. The prevalence of hazardous drinking and substance use at baseline was 37% and 24%, respectively. Hazardous drinking was highest in Cape Town (53%). Substance use was highest in Johannesburg (31%). Cannabis (7%) and sedatives (6%) were the most frequently used substances. Hazardous drinking (aOR=1.55, 95%CI = 1.05-2.29) was associated with increasing odds of low PrEP adherence. Substance use was not associated with low PrEP adherence. There is a need for increased screening for hazardous drinking and substance use and its integration within PrEP programs in AGYW in Africa.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.